SCHEMBL10037571

SCHEMBL10037571

CC(NC(=O)C(C)N1C(=O)C=CC1=O)NC(C)NC(C)NC(C)NC(=O)C(C)N1C(=O)C=CC1=O

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 2/20 0.37
▸ ALDH1A1 P00352 4/20 0.33
▸ HTT P42858 2/20 0.33
▸ LMNA P02545 2/20 0.33
▸ SMN1; SMN2 Q16637 2/20 0.32
▸ ALOX15 P16050 1/20 0.32
▸ MAPK1 P28482 1/20 0.32
▸ SLC1A2 P43004 1/20 0.32
▸ CYP1A2 P05177 1/20 0.31
▸ CYP3A4 P08684 1/20 0.31
▸ CYP2C9 P11712 1/20 0.31
▸ CYP2C19 P33261 1/20 0.31
▸ MAPT P10636 1/20 0.31
▸ KDM4E B2RXH2 1/20 0.31
▸ HSD17B10 Q99714 1/20 0.30
▸ HPGD P15428 1/20 0.30
▸ MMP1 P03956 1/20 0.30
▸ MMP2 P08253 1/20 0.30
▸ MMP9 P14780 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13185397 0.86 POLB (0.37) POLBALDH1A1HTTLMNASMN1; SMN2
SCHEMBL2610530 0.84 POLB (0.36) POLBALDH1A1HTTLMNASMN1; SMN2
SCHEMBL12107536 0.83 CYP1A2 (0.43) POLBALDH1A1HTTLMNASMN1; SMN2
SCHEMBL13448309 0.81 POLB (0.35) POLBALDH1A1HTTLMNASMN1; SMN2
SCHEMBL10310647 0.81 POLB (0.35) POLBALDH1A1HTTLMNASMN1; SMN2
SCHEMBL327611 0.80 SMN1; SMN2 (0.35) POLBALDH1A1HTTLMNASMN1; SMN2
SCHEMBL10037551 0.80 POLB (0.38) POLBALDH1A1HTTLMNASMN1; SMN2
SCHEMBL10037527 0.78 CPB2 (0.34) POLBSLC1A2MAPT
SCHEMBL12505905 0.78 HTT (0.35) POLBHTTMAPK1
SCHEMBL19543492 0.77 POLB (0.39) POLBALDH1A1HTTLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124791-B2 Active energy ray curable liquid composition and liquid cartridge CANON KABUSHIKI KAISHA (JP) 2012-02-28 — — US disclosed
US-20100094024-A1 ACTIVE ENERGY RAY CURABLE LIQUID COMPOSITION AND LIQUID CARTRIDGE CANON KABUSHIKI KAISHA (JP) 2010-04-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100094024-A1 ACTIVE ENERGY RAY CURABLE LIQUID COMPOSITION AND LIQUID CARTRIDGE C9, MLX, CHRM1 POLB 207/4885ALDH1A1 3555/4885HTT 4480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback